BlossomHill Therapeutics reports Q2 net loss and upsized IPO
BlossomHill Therapeutics reported a Q2 2026 net loss of $23.8M, ended June with $95.4M cash, and raised $168.3M gross in an upsized IPO. The company expects cash to fund operations into Q2 2028.
BlossomHill Therapeutics said its Q2 2026 net loss widened to $23.8M as research and development and general and administrative costs increased. The company ended June with $95.4M in cash. In August, BlossomHill said it raised $168.3M gross in an upsized IPO and expects that cash to fund operations into Q2 2028.